Trials / Completed
CompletedNCT04840485
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase II/III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Active Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 548 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1314 | SHR-1314 high dose |
| DRUG | SHR-1314 | SHR-1314 low-dose |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-06-09
- Primary completion
- 2023-11-03
- Completion
- 2024-02-28
- First posted
- 2021-04-12
- Last updated
- 2024-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04840485. Inclusion in this directory is not an endorsement.